Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

• Revenue in USD (TTM)0.00
• Net income in USD-314.85m
• Incorporated2017
• Employees479.00

• Location
  Replimune Group Inc500 Unicorn Park DrWOBURN 01801-3377United StatesUSA
• Phone+1 (781) 222-9600
• Fax+1 (302) 655-5049
• Websitehttps://www.replimune.com/